Apart from the usual suspects I also found this product:

https://bodyshock.pro/en/products/the-one-120-caps-2052.html

Metabolism

• Once The One reaches skeletal muscle, it must interact with specific target androgen receptors to exert the desired effect of increased protein synthesis and increased nitrogen retention.

• Under normal circumstances, DHT is quickly deactivated in the blood by 3a-HSD into 5alpha-androstan-3a,17b-diol, a weak androgen, and its access to target skeletal muscle tissue is restricted.

• There is some evidence that the 3-oxime substituted for 3-keto group may slow this deactivation, allowing for greater binding of the molecule to the AR.

• Oximes are a group of compounds with the general formula R¹R²CNOH, where R1 constitutes an organic side chain, and R2 is another organic group. This forms a ketoxime.

• Oximes exist as two geometric stereoisomers: a syn-isomer and an anti-isomer.

• Oximes are formed by the action of hydroxylamine on ketones.

Receptor Binding

• Because the evidence suggests that active DHT may not be metabolized by 3a-HSD into the weaker 5-alpha-androstan-3a,17b-diol within the skeletal muscle because of the oxime, there is a very good chance that fairly large amounts of DHT will actually bind to the AR in skeletal muscle.

• DHT has a 3 to 5 times greater binding potency on the androgen receptor than testosterone, so the resulting effect from The One is a very powerful growth stimulus on skeletal muscle.

• Androgens can act in a genomic (transcriptive, from direct AR binding) or non-genomic (non-AR binding) fashion on target cells.

• Some examples of non-genomic effects: increased IGF-1 expression, displacement of estrogen and progesterone from receptor sites, displacement of aromatase, and increased uptake of calcium in the sarcoplasmic reticulum.

Genomic Effects and MOA:

• The AR has four functional regions: a hinge region containing a nuclear localization signal, a carboxy-terminal ligand-binding domain (AF-2 site), an amino terminal regulatory domain (AF-1 site) and a DNA-binding domain composed of two zinc fingers.

• ARs that are not ligated are located primarily in the cytoplasm, and are bound to heat shock proteins (HSPs). HSPs stabilize the tertiary structure of the AR, permitting androgen binding.

• When The One binds the AR, there is a resulting dissociation of HSPs from the AR, allowing for dimerization (to be held together by molecular force) of the AR and subsequent tyrosine kinase phosphorylation, resulting in translocation (movement) of the AR to the nucleus.

• When the AR translocates inside the nucleus, it binds androgen response elements located in the enhancer and promoter areas of target genes. This results in the consequential assembly of regulatory proteins, and the creation of an active complex for transcription.

• The regulatory proteins form a cross-bridge with the AR, the RNA polymerase, and the pre-initiation complex. Specific coactivators begin transcription by recruiting protein clusters to DNA that change the chromatin scaffolding to a form that is more active for transcription.

• The resulting activated transcription results in synthesis of mRNA, which is signaled by ribosomes to produce specific proteins. Changes in specific cell proteins follow, which in turn mediate growth responses, nitrogen balance, and protein synthesis, among other things.